WebDovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50 s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. For research use only. We do not sell to patients. Dovitinib-d8 Chemical Structure CAS No. : 1246819-84-0 * Please select Quantity before … WebDescription: Dovitinib, also known as TKI-258 or CHIR-258, is an orally bioavailable FGFR3 inhibitor, which strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death.
Dovitinib lactate TKI-258 CHIR-258 CAS#804551-71-1
WebMay 15, 2005 · CHIR-258 exhibits properties that make it a promising candidate for clinical develop … These studies provide evidence that biological activity of CHIR-258 in tumors correlates with efficacy and aids in the identification of potential biomarkers of this multitargeted receptor tyrosine kinase inhibitor. WebDovitinib (TKI-258/CHIR-258) is a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT. It has shown efficacy in mouse-model of PCa bone metastasis, and is presently in clinical trials for several cancers. great granddaughter 4th birthday card
A Phase I Trial of CHIR-258, a Multitargeted RTK Inhibitor, in Acute ...
WebNov 16, 2004 · Dovitinib (TKI258; formerly CHIR-258) is an orally bioavailable inhibitor of a number of RTKs [5]. It targets several members of the class III, IV and V RTK family, including vascular endothelial ... WebDovitinib (CHIR-258; 10-60 mg/kg/day; gavage; for 21 days) has a significant antitumor effect [1]. Dovitinib (50 and 75 mg/kg) results in 97% and 98% tumor growth inhibition, respectively, and the maximal efficacy … WebJul 20, 2005 · CHIR-258 has ≤10 nmol/L activity against VEGF1/2/3 kinases, and our data clearly showed that CHIR-258 can inhibit autocrine VEGF levels in MV4;11 in vitro … great granddaughter 1st birthday wishes